- Consumer Products
- Latest 70.16
- Currency US$
- Change 0.54
- Percent Change 0.776 %
- Volume 657,596
- Fri Dec 6, 2013 04:00 PM EST NASDAQ data delayed 15 minutes.
12 months ended Sep 30, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Oct 24||$-0.28||Feb 20||$-0.34|
12 months ended Dec 06, 2013.
A look at major corporate events and financial announcements that are coming up.
About the Company
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.